Integra LifeSciences Holdings Corp. (IART) experienced a significant pre-market plunge of 5.44% on Tuesday, February 25, 2025, as the medical device maker reported disappointing fourth-quarter results and provided weaker-than-expected guidance for the first quarter and full-year 2025.
The company reported Q4 2024 revenue of $442.6 million, falling short of analyst estimates of $445.1 million. Adjusted earnings per share (EPS) of $0.97 for the quarter beat expectations of $0.86, but the revenue miss overshadowed the earnings beat.
For the first quarter of 2025, Integra LifeSciences expects revenue in the range of $375 million to $385 million, well below analyst estimates of around $411.7 million. The company also guided for adjusted EPS between $0.40 and $0.45 for the quarter.
Furthermore, the company's full-year 2025 revenue guidance of $1.65 billion to $1.71 billion fell slightly short of analyst expectations of around $1.71 billion, adding to investor concerns about the company's growth prospects.
Analysts cited the weaker-than-anticipated revenue guidance as the primary reason for the stock's pre-market decline, as investors reevaluated Integra LifeSciences' near-term growth trajectory and potential headwinds.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。